List of Excipients in Branded Drug ACETAZOLAMIDE EXTENDED-RELEASE

« Back to Dashboard

Generic Drugs Containing ACETAZOLAMIDE EXTENDED-RELEASE

Company	Ingredient	NDC	Excipient
Micro Labs Limited	acetazolamide extended-release	42571-243	ALCOHOL
Micro Labs Limited	acetazolamide extended-release	42571-243	AMMONIA
Micro Labs Limited	acetazolamide extended-release	42571-243	BUTYL ALCOHOL
Micro Labs Limited	acetazolamide extended-release	42571-243	CELLULOSE, MICROCRYSTALLINE
Micro Labs Limited	acetazolamide extended-release	42571-243	D&C RED NO. 28
Micro Labs Limited	acetazolamide extended-release	42571-243	D&C YELLOW NO. 10

What are the Most Frequently-Used Excipients in ACETAZOLAMIDE EXTENDED-RELEASE?

# Of NDCs	Excipient
3	ALCOHOL
3	AMMONIA
3	BUTYL ALCOHOL
3	CELLULOSE, MICROCRYSTALLINE
3	D&C RED NO. 28
3	D&C YELLOW NO. 10

Acetazolamide Extended-Release Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Acetazolamide extended-release is a mature, low-barrier oral product opportunity centered on 500 mg modified-release capsules. The strongest commercial strategy is not primary-compound patenting. It is reliable release control, food-effect management, differentiated capsule design, and manufacturing economics. Brand and generic products compete in a small therapeutic market spanning glaucoma, altitude illness, edema, epilepsy adjunct treatment, and idiopathic intracranial hypertension.

What is acetazolamide extended-release and how is it used?

Acetazolamide is a carbonic anhydrase inhibitor. The extended-release product is generally supplied as a 500 mg capsule and is marketed to reduce dosing frequency compared with immediate-release acetazolamide tablets.[1]

The FDA-approved product label identifies the following principal uses:

• Open-angle glaucoma
• Secondary glaucoma
• Preoperative treatment of acute angle-closure glaucoma
• Abnormal fluid retention associated with congestive heart failure
• Drug-induced edema
• Adjunctive treatment of epilepsy
• Prevention or mitigation of acute mountain sickness

Acetazolamide is also widely used off label for idiopathic intracranial hypertension, periodic paralysis, and selected neurologic or sleep-related disorders. These uses expand demand but do not necessarily create additional FDA-recognized market exclusivity.

The commercial product is generally administered once or twice daily, depending on the indication and clinical response. The extended-release presentation reduces the number of daily doses relative to 250 mg immediate-release tablets.

What excipients are used in acetazolamide extended-release capsules?

The commercial excipient system is designed to slow dissolution while maintaining capsule manufacturability and dose uniformity. Product labeling should be used to confirm the exact inactive-ingredient composition for each marketed product because generic manufacturers may use different excipient systems.[1]

Typical formulation functions include:

Formulation function	Common excipient classes	Commercial purpose
Release control	Hypromellose, ethylcellulose, polymers, lipidic materials	Slows drug release over the intended dosing interval
Granulation and binding	Povidone, hypromellose, starch derivatives	Improves granule strength and content uniformity
Dilution	Lactose, microcrystalline cellulose, starches	Provides capsule fill volume and processability
Lubrication	Magnesium stearate, stearic acid	Reduces friction during capsule filling
Flow improvement	Colloidal silicon dioxide, talc	Improves powder flow and fill-weight consistency
Capsule shell	Gelatin or hypromellose	Provides the dosage-form enclosure
Color and opacity	Titanium dioxide and approved colorants	Supports product identification and light protection

The key technical issue is not simply selecting a polymer. Acetazolamide release depends on particle size, drug loading, granule porosity, polymer viscosity, coating weight, dissolution medium, and capsule-fill density. Small changes in these variables can alter the early release fraction and total release duration.

Which excipient approaches are most suitable?

A hydrophilic matrix is the most direct development route. Hypromellose hydrates after ingestion and forms a gel layer that controls water penetration and drug diffusion. It is relatively inexpensive, broadly used, and familiar to regulators.

A hydrophobic matrix based on ethylcellulose or lipid excipients can provide stronger release retardation, particularly where a hydrophilic matrix releases too rapidly. The tradeoff is greater process sensitivity and a higher risk of incomplete release or batch-to-batch variability.

A multiparticulate system can separate acetazolamide into coated pellets or granules. This approach can improve release consistency and permit capsule filling at different strengths. It also creates more opportunities for formulation patent claims covering:

• Core composition
• Polymer coating layers
• Coating weight gain
• Particle-size distribution
• Release profiles
• Capsule combinations
• Food-effect control

Multiparticulates generally require more complex manufacturing and analytical controls than a conventional matrix capsule. Their commercial value is greatest when they produce a measurable advantage in fed-state performance, tolerability, or dosing flexibility.

How should an acetazolamide extended-release formulation be optimized?

The target product profile should emphasize consistent exposure rather than the longest possible release period. Acetazolamide has clinically important renal and acid-base effects, so excessive dose dumping or high early exposure could create safety and tolerability concerns.

Priority development variables include:

1. Initial release control during the first two to four hours.
2. Completion of drug release within the gastrointestinal transit window.
3. Limited sensitivity to gastric pH.
4. Low sensitivity to high-fat meals.
5. Robust capsule-fill weight and content uniformity.
6. Stability under standard heat and humidity conditions.
7. Compatibility with high-speed encapsulation.

Acetazolamide has limited aqueous solubility in its neutral form and pH-dependent dissolution behavior. Particle-size reduction may improve dissolution but can undermine extended release by increasing surface area. A formulation should therefore control both drug particle size and polymer structure.

How can excipients improve tolerability?

Acetazolamide can cause paresthesia, gastrointestinal symptoms, altered taste, polyuria, fatigue, and metabolic acidosis. Excipients cannot eliminate mechanism-related adverse effects, but formulation design can reduce peak-related intolerance.

Potential approaches include:

• Lowering the early dissolution fraction.
• Avoiding large differences between fed and fasted exposure.
• Using a smooth release curve rather than a rapid initial pulse.
• Reducing capsule shell volume through higher-density fills.
• Offering lactose-free or color-free versions for selected markets.
• Using hypromellose capsules for customers seeking non-gelatin products.

These claims require clinical or bioequivalence support. A smoother in vitro profile alone does not establish improved tolerability.

What FDA regulatory pathway applies to acetazolamide extended-release?

A conventional generic version of the reference extended-release capsule would normally proceed through an abbreviated new drug application under section 505(j) of the Federal Food, Drug, and Cosmetic Act. The applicant must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug.[2]

The principal regulatory workstreams are:

• Same active ingredient, strength, dosage form, and route.
• Comparable extended-release performance.
• Pharmacokinetic bioequivalence.
• Fed and fasting evaluations where required.
• Stability data for the proposed formulation.
• Inactive-ingredient justification.
• Dissolution method development and comparative profiles.
• Manufacturing controls for polymer distribution and coating performance.

A materially different delivery system, new dosing concept, or clinically meaningful change in labeling could move the product toward a 505(b)(2) strategy. That route is more relevant to a reformulated product than to a standard generic capsule, but it carries higher clinical and regulatory costs.

The FDA’s product-specific guidance and ANDA review history should be checked before locking the development program. Modified-release products often face greater review scrutiny than immediate-release solid oral products because bioequivalence can be sensitive to food, dissolution methodology, and formulation architecture.[3]

What patents protect acetazolamide extended-release products?

Acetazolamide is an old small-molecule drug. Its compound patent and original regulatory exclusivity have expired. The principal intellectual-property opportunity is therefore formulation, manufacturing, or use-based protection rather than active-ingredient protection.

Potential patent claim categories include:

• Extended-release matrix compositions.
• Coated multiparticulates.
• Specific polymer ratios.
• Defined dissolution windows.
• Reduced food-effect formulations.
• Low-dose or high-dose capsule configurations.
• Capsule-in-capsule systems.
• Methods for treating idiopathic intracranial hypertension.
• Methods for preventing altitude sickness with a particular dosing schedule.
• Manufacturing processes that improve content uniformity or stability.

Method-of-use patents face substantial vulnerability where the indication or dosing concept is already well established. Formulation claims are more commercially relevant, but their strength depends on narrow technical limitations that competitors cannot easily design around.

The FDA Orange Book should be reviewed for current listed patents and regulatory exclusivities associated with the reference product.[4] For a mature acetazolamide extended-release product, the likely commercial risk comes from generic substitution and price competition rather than a strong active patent estate.

When does acetazolamide extended-release lose exclusivity?

Acetazolamide extended-release is already a mature product category. New chemical entity exclusivity is not relevant to the current opportunity, and any original product patents would generally have expired.

The key exclusivity questions are product-specific:

Exclusivity category	Relevance to acetazolamide extended-release
New chemical entity exclusivity	Expired
Original compound patent	Expired
Pediatric exclusivity	Not a durable current barrier unless specifically listed
Formulation patent	Must be checked in the current Orange Book and patent records
Method-of-use patent	May affect only a labeled indication and may not block all generic sales
180-day generic exclusivity	Could temporarily affect a first approved Paragraph IV applicant if statutory conditions are met

A generic applicant should assess not only listed patents but also litigation history, delisting events, patent-term calculations, and any settlement agreements.

How strong is the patent estate for acetazolamide extended-release?

The overall patent estate is likely weak to moderate from a blocking perspective and potentially stronger for narrow formulation improvements.

IP layer	Expected blocking strength	Commercial assessment
Acetazolamide molecule	Low	Expired technology
Basic 500 mg extended-release capsule	Low to moderate	Mature dosage-form concept
Specific polymer matrix	Moderate	May support a narrow formulation patent
Multiparticulate coating system	Moderate to high if technically distinctive	More difficult to copy exactly
Manufacturing process	Low to moderate	Useful for cost or quality differentiation
Method of use	Low to moderate	Often indication-specific and vulnerable to design-around
Trade secrets	Moderate operational value	Can protect process know-how without delaying generic entry

Patent strength will depend on claim scope, written description, prosecution history, and whether the formulation delivers a demonstrable pharmacokinetic or dissolution advantage.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV certification could target any unexpired Orange Book-listed patent. For an old acetazolamide product, the most plausible targets would be formulation or method-of-use patents, not the active compound.

The litigation risk is generally lower than for high-value chronic medicines because the market is comparatively small and generic development costs are limited. A first filer could still litigate if a listed formulation patent has meaningful commercial value or if few competitors have entered.

Key litigation scenarios include:

• Certification that a listed formulation patent is invalid.
• Certification that the proposed generic does not infringe.
• Declaratory judgment litigation after a patent-holder response.
• Settlement with a delayed generic launch.
• Carve-out of a patented method of use.
• Launch at risk after the 30-month stay expires or after favorable litigation results.

The commercial impact of a settlement would depend on the number of other approved or pending ANDAs. A settlement has less value when several generic applicants can enter independently.

What commercial opportunities exist for acetazolamide extended-release?

The opportunity is best suited to companies with existing oral solid-dose infrastructure, established ANDA capabilities, and low-cost encapsulation or coating operations.

Generic 500 mg capsule

The most direct opportunity is a therapeutically equivalent 500 mg extended-release capsule. Success depends on:

• Bioequivalence on the first or second submission cycle.
• Low manufacturing cost.
• Reliable supply.
• Competitive wholesaler pricing.
• Broad pharmacy substitution.
• Stable reimbursement across Medicare, Medicaid, and commercial plans.

Because acetazolamide is an older generic product, price erosion can be rapid after multiple entrants. The product can still generate attractive returns if development uses existing equipment and the company avoids major clinical reformulation work.

Differentiated excipient versions

A differentiated version could target:

• Lactose-free composition.
• Gelatin-free capsule shell.
• Color-free presentation.
• Improved moisture stability.
• Reduced food effect.
• Lower variability in early exposure.
• Smaller capsule size.
• More efficient once-daily dosing, if clinically supported.

These attributes are more likely to support contracting, international registration, or niche pharmacy demand than premium pricing in the U.S. generic market.

Hospital and specialty distribution

Acetazolamide has recurring use in ophthalmology, neurology, emergency care, travel medicine, and altitude clinics. A supplier with dependable availability can gain share during shortages or wholesaler disruptions. Institutional demand may favor standardized packaging, unit-dose formats, and reliable short-dated inventory management.

Geographic expansion

Markets with limited access to extended-release acetazolamide may offer better margins than the highly competitive U.S. generic market. Registration strategy should account for:

• Local reference-product requirements.
• Modified-release bioequivalence standards.
• Capsule-shell restrictions.
• Excipient permissibility.
• Pharmacopoeial dissolution methods.
• Local altitude-medicine demand.
• Government tender pricing.

The same formulation may not be optimal globally if excipient acceptance, capsule labeling, or bioequivalence requirements differ.

How does acetazolamide extended-release compare with immediate-release acetazolamide?

Attribute	Extended-release capsule	Immediate-release tablet
Typical strength	500 mg	125 mg or 250 mg
Dosing burden	Lower	Higher
Formulation complexity	High	Low
Bioequivalence risk	Higher	Lower
Manufacturing cost	Higher	Lower
Differentiation potential	Moderate	Limited
Food-effect sensitivity	Must be characterized	Usually simpler
Generic competition	Established	Established
Patent opportunity	Formulation-focused	Very limited

The extended-release product has greater formulation complexity but also a clearer value proposition. Immediate-release tablets are easier to manufacture and may win on price. Extended-release capsules can compete on dosing convenience and adherence, particularly for patients requiring long-term therapy.

What generic launch risks exist for acetazolamide extended-release?

The principal risks are technical and commercial:

• Failure to match the reference product under fed conditions.
• Dose dumping during early dissolution.
• Incomplete release at higher pH.
• Capsule-fill variability.
• Polymer lot variability.
• Low market price after multiple approvals.
• Limited pharmacy demand for a second or third generic.
• Substitution of immediate-release tablets by prescribers.
• Weak reimbursement for differentiated excipient versions.
• Manufacturing disruption caused by specialized coating steps.

A staged development program should first establish a conventional, regulatorily conservative formulation. More complex excipient strategies should be pursued only if they create a measurable performance or market-access advantage.

Key Takeaways

• Acetazolamide extended-release is a mature 500 mg modified-release capsule opportunity.
• The active ingredient does not provide meaningful current patent protection.
• The main technical value lies in polymer selection, release control, food-effect management, and manufacturing consistency.
• Hydrophilic matrices are the lowest-complexity development route; multiparticulates offer stronger differentiation but higher cost.
• A standard ANDA is the likely regulatory pathway for a therapeutically equivalent product.
• Formulation and manufacturing patents may protect narrow innovations, but they are unlikely to create a broad market blockade.
• Commercial returns depend on low-cost development, first-cycle approval, reliable supply, and disciplined launch timing.
• The most credible differentiation opportunities are lactose-free or gelatin-free products, improved release consistency, smaller capsules, and international market access.
• Immediate-release tablets remain a lower-cost competitive substitute.
• FDA Orange Book review and current product-specific guidance are necessary for a live patent and exclusivity assessment.[3][4]

FAQs about acetazolamide extended-release excipients and market entry

Can acetazolamide extended-release be formulated as a tablet instead of a capsule?

Yes. A tablet could use a hydrophilic or hydrophobic matrix, but the reference product’s dosage form and release characteristics would determine the regulatory pathway. A tablet may require a 505(b)(2) application or additional bioequivalence justification if it is not pharmaceutically equivalent to the reference capsule.

Is lactose a necessary excipient in acetazolamide extended-release capsules?

No. Lactose may provide useful bulk and processability, but microcrystalline cellulose, starches, mannitol, or other suitable diluents can be evaluated. The replacement must preserve content uniformity, dissolution, stability, and bioequivalence.

Can a manufacturer patent a new acetazolamide extended-release excipient system?

Yes, if the formulation is novel, non-obvious, adequately described, and supported by reproducible technical results. Stronger claims usually connect the excipient system to a defined dissolution or pharmacokinetic performance.

Is acetazolamide extended-release suitable for a 505(b)(2) product?

It can be, particularly where the sponsor proposes a materially different delivery system, dosing regimen, or patient-use profile. A conventional generic equivalent is more naturally pursued through the ANDA pathway.

Does acetazolamide extended-release have biosimilar competition risk?

No. Acetazolamide is a synthetic small molecule, not a biologic. Competition arises through generic drug applications, not biosimilar applications.

References

1. U.S. Food and Drug Administration. (n.d.). Diamox Sequels: Acetazolamide extended-release capsules prescribing information. DailyMed.

2. U.S. Food and Drug Administration. (2024). Abbreviated new drug application (ANDA) process. https://www.fda.gov/drugs/abbreviated-new-drug-application-anda

3. U.S. Food and Drug Administration. (2024). Product-specific guidances for generic drug development. https://www.fda.gov/drugs/guidances-drugs/product-specific-guidances-generic-drug-development

4. U.S. Food and Drug Administration. (2024). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm